A Phase 2 interventional study of Decitabine in Myelodysplastic Syndrome, sponsored by Eisai Inc.. Completed at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-20.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 19th largest by enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2005, is one of 36 in phase 2, and was the 10th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 7 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Decitabine
20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
Also known as: Dacogen
Number of Participants Who Achieved Overall Response
Overall Response = complete remission (disappearance of all target lesions) + partial remission (at least 30% decrease in the sum of the longest diameters of target lesions)
Time frame: 1 year
Best Response and Overall Improvement
Overall Improvement = complete remission + marrow complete remission + partial remission + hematologic improvement (CR+mCR+PR+HI)
Time frame: 1 year
| Milestone | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Started | 99 |
| Completed | 6 |
| Not completed | 93 |
| Withdrew: Progressive disease | 22 |
| Withdrew: Adverse event | 17 |
| Withdrew: Death | 13 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Physician decision | 19 |
| Withdrew: Not otherwise specified | 8 |
| Withdrew: Medication noncompliance | 1 |
Overall Response = complete remission (disappearance of all target lesions) + partial remission (at least 30% decrease in the sum of the longest diameters of target lesions)
| participants | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Number of Participants Who Achieved Overall Response | 33 |
Overall Improvement = complete remission + marrow complete remission + partial remission + hematologic improvement (CR+mCR+PR+HI)
| Participants | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Overall Improvement | 51 |
| Complete Remission (CR) | 17 |
| Marrow Complete Remission (mCR) | 16 |
| Partial Remission (PR) | 0 |
| Hematologic Improvement (HI) | 18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine 20 mg/m2 Intravenous | — | 65/99 (65.7%) | 96/99 (97%) |
| Event | Decitabine 20 mg/m2 Intravenous |
|---|---|
| PneumoniaInfections and infestations | 17/99 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 13/99 |
| NeutropeniaBlood and lymphatic system disorders | 12/99 |
| AnaemiaBlood and lymphatic system disorders | 9/99 |
| Staphylococcal BacteraemiaInfections and infestations | 7/99 |
| PyrexiaGeneral disorders | 6/99 |
| PancytopeniaBlood and lymphatic system disorders | 4/99 |
| Disease ProgressionGeneral disorders | 4/99 |
| SepsisInfections and infestations | 4/99 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/99 |
| Event | Decitabine 20 mg/m2 Intravenous |
|---|---|
| FatigueGeneral disorders | 46/99 |
| NauseaGastrointestinal disorders | 40/99 |
| NeutropeniaBlood and lymphatic system disorders | 38/99 |
| PyrexiaGeneral disorders | 36/99 |
| AnaemiaBlood and lymphatic system disorders | 31/99 |
| ConstipationGastrointestinal disorders | 30/99 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 29/99 |
| DiarrheaGastrointestinal disorders | 28/99 |
| ThrombocytopeniaBlood and lymphatic system disorders | 27/99 |
| Oedema PeripheralGeneral disorders | 27/99 |
| Age, Categorical(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 15 |
| >=65 years | 84 |
| Age Continuous(years) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Mean | 70.9 ± 8.78 |
| Sex: Female, Male(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| Female | 28 |
| Male | 71 |
| Race (NIH/OMB)(Participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 86 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Decitabine 20 mg/m2 Intravenous |
|---|---|
| United States | 99 |
The record gives a start of May 2005, a primary completion of Jun 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine